Abstract
The Clinical Pharmacogenetics Implementation Consortium (CPIC) publishes genotype-based drug guidelines to help clinicians understand how available genetic test results could be used to optimize drug therapy. CPIC has focused initially on well-known examples of pharmacogenomic associations that have been implemented in selected clinical settings, publishing nine to date. Each CPIC guideline adheres to a standardized format and includes a standard system for grading levels of evidence linking genotypes to phenotypes and assigning a level of strength to each prescribing recommendation. CPIC guidelines contain the necessary information to help clinicians translate patient-specific diplotypes for each gene into clinical phenotypes or drug dosing groups. This paper reviews the development process of the CPIC guidelines and compares this process to the Institute of Medicine’s Standards for Developing Trustworthy Clinical Practice Guidelines.
Keywords: Clinical practice guideline, guideline, pharmacogenetics, pharmacogenomics.
Current Drug Metabolism
Title:Incorporation of Pharmacogenomics into Routine Clinical Practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline Development Process
Volume: 15 Issue: 2
Author(s): Vojtech Huser, Samuel G. Johnson, Marc S. Williams, Mary V. Relling, Dan Roden, C. Michael Stein, Rachel F. Tyndale, Jesse J. Swen, Mia Wadelius, Stuart A. Scott, Kristine R. Crews, Otito F. Iwuchukwu, Ming Ta Michael Lee, Kelly E. Caudle, Robert R. Freimuth, Jose A.G. Agundez, Matthias Schwab, Caroline F. Thorn, Katrin Sangkuhl, Ellen M. McDonagh, Li Gong, Michelle Whirl-Carrillo, Daniel J. Muller, James M. Hoffman and Teri E. Klein
Affiliation:
Keywords: Clinical practice guideline, guideline, pharmacogenetics, pharmacogenomics.
Abstract: The Clinical Pharmacogenetics Implementation Consortium (CPIC) publishes genotype-based drug guidelines to help clinicians understand how available genetic test results could be used to optimize drug therapy. CPIC has focused initially on well-known examples of pharmacogenomic associations that have been implemented in selected clinical settings, publishing nine to date. Each CPIC guideline adheres to a standardized format and includes a standard system for grading levels of evidence linking genotypes to phenotypes and assigning a level of strength to each prescribing recommendation. CPIC guidelines contain the necessary information to help clinicians translate patient-specific diplotypes for each gene into clinical phenotypes or drug dosing groups. This paper reviews the development process of the CPIC guidelines and compares this process to the Institute of Medicine’s Standards for Developing Trustworthy Clinical Practice Guidelines.
Export Options
About this article
Cite this article as:
Huser Vojtech, Johnson G. Samuel, Williams S. Marc, Relling V. Mary, Roden Dan, Stein Michael C., Tyndale F. Rachel, Swen J. Jesse, Wadelius Mia, Scott A. Stuart, Crews R. Kristine, Iwuchukwu F. Otito, Michael Lee Ta Ming, Caudle E. Kelly, Freimuth R. Robert, Agundez A.G. Jose, Schwab Matthias, Thorn F. Caroline, Sangkuhl Katrin, McDonagh M. Ellen, Gong Li, Whirl-Carrillo Michelle, Muller J. Daniel, Hoffman M. James and Klein E. Teri, Incorporation of Pharmacogenomics into Routine Clinical Practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline Development Process, Current Drug Metabolism 2014; 15 (2) . https://dx.doi.org/10.2174/1389200215666140130124910
DOI https://dx.doi.org/10.2174/1389200215666140130124910 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |
Call for Papers in Thematic Issues
Interaction between drugs and endocrine diseases
The introduction of highly active antiretroviral therapy accelerated studies and our understanding on the interaction between pharmacological therapies and endocrine diseases. Drugs can precipitate endocrine via different mechanisms, including direct alteration of hormone production and secretion, dysregulation of hormonal axis, effects on hormonal transport, receptor-binding, and cellular signalling. Common drug-induced ...read more
Tissue Distribution and Metabolism of Micro- and Nanoparticles and Medical Implants
With the continuous advancement of modern science and engineering, numerous functional materials and active molecules have been developed and utilized in various industrial, medical, and food applications. Many of these can enter the body, either actively or passively, and have significant and intricate impacts on human health. For example, biomaterials ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Sleep and COPD
Current Respiratory Medicine Reviews Word Forms of Modern Japanese Sound Symbolic Words Not Listed in Dictionaries
Neuroscience and Biomedical Engineering (Discontinued) Pro-Inflammatory Cytokines IL-1β and TNF-α are not Associated with Plasma Homocysteine Concentration in Alzheimer’s Disease
Current Alzheimer Research Inhibition of Efflux of Quinolines as New Therapeutic Strategy in Malaria
Current Topics in Medicinal Chemistry Monoclonal Antibodies - Regulatory Challenges
Current Pharmaceutical Biotechnology Elevated Testosterone Level and Urine Scent Marking in Male 5xFAD Alzheimer Model Mice
Current Alzheimer Research Pharmacological Neuroprotection after Perinatal Hypoxic-Ischemic Brain Injury
Current Neuropharmacology Targeting Striatal Metabotropic Glutamate Receptor Type 5 in Parkinson’s Disease: Bridging Molecular Studies and Clinical Trials
CNS & Neurological Disorders - Drug Targets The Roles of Parathyroid Hormone and Calcitonin in Bone Remodeling: Prospects for Novel Therapeutics
Endocrine, Metabolic & Immune Disorders - Drug Targets Cardiac and Metabolic Consequences of Aerobic Exercise Training in Experimental Diabetes
Current Diabetes Reviews In Vivo Beta-Cell Imaging with VMAT 2 Ligands - Current State-of-the-Art and Future Perspectives
Current Pharmaceutical Design Glucocorticoids in Pregnancy
Current Pharmaceutical Biotechnology Obesity Pharmacotherapy: Current Perspectives and Future Directions
Current Cardiology Reviews “Nutritional Psychiatry: Evidence of the Role of Foods in Mental Health” Part 1
Current Pharmaceutical Biotechnology Resilient Brain Aging: Characterization of Discordance between Alzheimer’s Disease Pathology and Cognition
Current Alzheimer Research State of the Art: Psychotherapeutic Interventions Targeting the Psychological Factors Involved in IBD
Current Drug Targets A New Series of 1,3-Dimethylxanthine Based Adenosine A<sub>2A</sub> Receptor Antagonists as a Non-Dopaminergic Treatment of Parkinson’s Disease
Current Drug Discovery Technologies Protein-Protein Interactions at the Adrenergic Receptors
Current Drug Targets Accessing Cancer Metabolic Pathways by the Use of Microarray Technology
Current Pharmaceutical Design Altered Mesolimbic Dopamine System in THC Dependence
Current Neuropharmacology